Relevance of bone marrow features in the differential diagnosis between essential thrombocythemia and early stage idiopathic myelofibrosis.
暂无分享,去创建一个
H M Kvasnicka | V. Diehl | J. Thiele | V Diehl | R Zankovich | J Thiele | H. Kvasnicka | R. Zankovich | Jürgen Thiele | Volker Diehl | J. Thiele
[1] M. Cappellini,et al. Survival and Disease Complications in Thalassemia Major , 1998, Annals of the New York Academy of Sciences.
[2] A. Reiter,et al. Should a platelet limit of 600 × 109/l be used as a diagnostic criterion in essential thrombocythaemia? An analysis of the natural course including early stages , 1998, British journal of haematology.
[3] J. Laszlo,et al. Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment. , 1997, Seminars in hematology.
[4] G. Aprili,et al. Subcutaneous bolus injection of deferoxamine in adult patients affected by onco-hematologic diseases and iron overload. , 1998, Haematologica.
[5] M. Hakama,et al. Estimating the expectation of life in cancer survival studies with incomplete follow-up information. , 1977, Journal of chronic diseases.
[6] T. Pearson. Diagnosis and classification of erythrocytoses and thrombocytoses. , 1998, Bailliere's clinical haematology.
[7] G. Link,et al. Iron Chelators for Thalassaemia , 1998, British journal of haematology.
[8] A. Hoffbrand. Oral iron chelation. , 1996, Seminars in hematology.
[9] Arturo Pereira,et al. Acute transformation in nonleukemic chronic myeloproliferative disorders: actuarial probability and main characteristics in a series of 218 patients. , 1991, Acta haematologica.
[10] S. Murphy. Diagnostic criteria and prognosis in polycythemia vera and essential thrombocythemia. , 1999, Seminars in hematology.
[11] V. Diehl,et al. Idiopathic primary osteo-myelofibrosis: a clinico-pathological study on 208 patients with special emphasis on evolution of disease features, differentiation from essential thrombocythemia and variables of prognostic impact. , 1996, Leukemia & lymphoma.
[12] P. Mazza,et al. Oral iron chelating therapy. A single center interim report on deferiprone (L1) in thalassemia. , 1998, Haematologica.
[13] M. Aglietta,et al. Ex vivo expansion of hematopoietic cells and their clinical use. , 1998, Haematologica.
[14] A. Piga,et al. Results of long-term iron-chelating therapy. , 1996, Acta haematologica.
[15] H. Hasselbalch,et al. A sequential histological study of bone marrow fibrosis in idiopathic myelofibrosis , 1991, European journal of haematology.
[16] F. Jensen,et al. Evaluation of transfusional iron overload before and during iron chelation by magnetic resonance imaging of the liver and determination of serum ferritin in adult non‐thalassaemic patients , 1995, British journal of haematology.
[17] J. Balfour,et al. Deferiprone: a review of its clinical potential in iron overload in beta-thalassaemia major and other transfusion-dependent diseases. , 1999, Drugs.
[18] S. Sacchi,et al. Alfa-interferon in the treatment of essential thrombocythemia: clinical results and evaluation of its biological effects on the hematopoietic neoplastic clone , 1998, Leukemia.
[19] P. Faccini,et al. Prognostic significance of bone marrow biopsy in essential thrombocythemia. , 1999, Haematologica.
[20] H. Wadenvik,et al. Diagnostic and differential criteria of essential thrombocythemia and reactive thrombocytosis. , 1996, Leukemia & lymphoma.
[21] K. Fleming,et al. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major. , 1998, The New England journal of medicine.
[22] B. Grandchamp,et al. Clonal analysis of haemopoietic cells in essential thrombocythaemia , 1995, British journal of haematology.
[23] A. Lanzavecchia. Dendritic cell maturation and generation of immune responses. , 1999, Haematologica.
[24] P. Morel,et al. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. , 1996, Blood.
[25] J. Vardiman,et al. Issues in the pathology and diagnosis of the chronic myeloproliferative disorders and the myelodysplastic syndromes. , 1993, American journal of clinical pathology.
[26] W. Wilmanns,et al. Potential of bone marrow biopsy in chronic myeloproliferative disorders (MPD) , 1993, European journal of haematology.
[27] V. Diehl,et al. Clinicopathological diagnosis and differential criteria of thrombocythemias in various myeloproliferative disorders by histopathology, histochemistry and immunostaining from bone marrow biopsies. , 1999, Leukemia & lymphoma.
[28] R. Fischer,et al. Prognostic factors in idiopathic (Primary) osteomyelofibrosis , 1997, Cancer.
[29] S. Pileri,et al. Myelofibrosis with myeloid metaplasia: clinical and haematological parameters predicting survival in a series of 133 patients , 1990, British journal of haematology.
[30] W. Swaim,et al. Primary thrombocythemia. , 1973, Geriatrics.
[31] P. Fenaux,et al. Clinical course of essential thrombocythemia in 147 cases , 1990, Cancer.
[32] R. Berger,et al. Essential thrombocythemias. Clinical evolutionary and biological data , 1986, Cancer.
[33] T. Reichert,et al. Differentiation between essential thrombocythemia and polycythemia vera with marked thrombocytosis , 1987, American journal of hematology.
[34] D. Weatherall,et al. Iron-chelating therapy. , 1988, Critical reviews in clinical laboratory sciences.
[35] A. Hoffbrand,et al. Iron chelation with oral deferiprone in patients with thalassemia. , 1998, The New England journal of medicine.
[36] A. Piperno. Classification and diagnosis of iron overload. , 1998, Haematologica.
[37] A. Georgii,et al. 2 The histopathology of chronic myeloproliferative diseases , 1998 .
[38] T. Hamblin,et al. DNA vaccines against haematological malignancies. , 1999, Haematologica.
[39] J. Michiels,et al. Normal Life Expectancy and Thrombosis-Free Survival in Aspirin Treated Essential Thrombocythemia , 1999, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.
[40] A. Georgii,et al. Classification and staging of Ph-negative myeloproliferative disorders by histopathology from bone marrow biopsies. , 1996, Leukemia & lymphoma.
[41] F. Sallusto. The role of chemokines and chemokine receptors in T cell priming and Th1/Th2-mediated responses. , 1999, Haematologica.
[42] A. Cohen,et al. Current status of iron chelation therapy with deferoxamine. , 1990, Seminars in hematology.
[43] R. Grady,et al. Iron chelation with oral deferiprone in patients with thalassemia. , 1998, New England Journal of Medicine.
[44] T. Hakulinen,et al. Cancer survival corrected for heterogeneity in patient withdrawal. , 1982, Biometrics.
[45] John B. Porter,et al. A Risk-Benefit Assessment of Iron-Chelation Therapy , 1997, Drug safety.
[46] K. Konstantopoulos,et al. Chelation therapy in patients with thalassemia using the orally active iron chelator deferiprone (L1). , 2000, Haematologica.
[47] T. Barbui,et al. Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[48] Smith Rs. Iron Excretion in Thalassaemia Major After Administration of Chelating Agents , 1962 .
[49] T. Pearson. 1 Diagnosis and classification of erythrocytoses and thrombocytoses , 1998 .
[50] A. Georgii,et al. The histopathology of chronic myeloproliferative diseases. , 1998, Bailliere's clinical haematology.
[51] C. Eaves,et al. Variable expression of features of normal and neoplastic stem cells in patients with thrombocytosis , 1992, British journal of haematology.
[52] S. Sacchi,et al. Progression of essential thrombocythemia to blastic crisis via idiopathic myelofibrosis. , 1993, Leukemia & lymphoma.
[53] A. Tefferi,et al. Interferon-α Therapy in Polycythemia Vera and Essential Thrombocythemia , 1997 .
[54] M. Colombo,et al. Cell therapy: achievements and perspectives. , 1999, Haematologica.
[55] R. Grady,et al. Chelation therapy in beta-thalassemia: the benefits and limitations of desferrioxamine. , 1995, Seminars in hematology.
[56] A. Vitale,et al. Essential thrombocythemia: a retrospective study on the clinical course of 100 patients. , 1990, Haematologica.
[57] M. Colombi,et al. Thrombotic and hemorrhagic complications in essential thrombocythemia. A retrospective study of 103 patients , 1991, Cancer.
[58] M. Pippard,et al. THE MANAGEMENT OF IRON CHELATION THERAPY , 1983, British journal of haematology.
[59] E. Juvonen,et al. Proposal for Revised Diagnostic Criteria of Essential Thrombocythemia and Polycythemia Vera by the Thrombocythemia Vera Study Group , 1997, Seminars in thrombosis and hemostasis.
[60] W. Anderson,et al. Continuous Subcutaneous Administration of Deferoxamine in Patients with Iron Overload , 1977 .
[61] M. Pippard. 4 Desferrioxamine-induced iron excretion in humans , 1989 .
[62] V. Diehl,et al. Agnogenic myeloid metaplasia (AMM)—correlation of bone marrow lesions with laboratory data: A longitudinal clinicopathological study on 114 patients , 1989, Hematological oncology.
[63] Riva,et al. No treatment for low‐risk thrombocythaemia:results from a prospective study , 1998, British journal of haematology.
[64] S. Landaw,et al. Essential thrombocythemia: clinical and laboratory characteristics at presentation. , 1983, Transactions of the Association of American Physicians.
[65] S. Sacchi,et al. Diagnosis of essential thrombocythemia at platelet counts between 400 and 600x10(9)/L. Gruppo Italiano Malattie Mieloproliferative Croniche(GIMMC). , 2000, Haematologica.
[66] E. Feliú,et al. Life expectancy of patients with chronic nonleukemic myeloproliferative disorders , 1991, Cancer.
[67] E. Ikkala,et al. Essential thrombocythemia at diagnosis: causes of diagnostic evaluation and presence of positive diagnostic findings , 1998, Annals of Hematology.
[68] A. Georgii,et al. Myelofibrosis in chronic myeloproliferative disorders. Incidence among subtypes according to the Hannover Classification. , 1993, Pathology, research and practice.
[69] C. Borgna-Pignatti,et al. Evaluation of a new method of administration of the iron chelating agent deferoxamine. , 1997, The Journal of pediatrics.
[70] R. Hehlmann,et al. Essential thrombocythemia. Clinical characteristics and course of 61 cases , 1988, Cancer.
[71] G. Aprili,et al. Safety and efficacy of subcutaneous bolus injection of deferoxamine in adult patients with iron overload. , 2000, Blood.
[72] M. Werner,et al. Chronic myeloproliferative disorders in bone marrow biopsies. , 1990, Pathology, research and practice.
[73] T. Einarson,et al. Meta-analytic review of the clinical effectiveness of oral deferiprone (L1) , 1999, European Journal of Clinical Pharmacology.
[74] D. Mason,et al. The immunohistological detection of platelets, megakaryocytes and thrombi in routinely processed specimens , 1988, Histopathology.
[75] H Stein,et al. Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). , 1984, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.
[76] V. Diehl,et al. Primary (essential) thrombocythemia versus initial (hyperplastic) stages of agnogenic myeloid metaplasia with thrombocytosis--a critical evaluation of clinical and histomorphological data. , 1989, Acta haematologica.
[77] S. Shurin,et al. Reassessment of the use of desferrioxamine B in iron overload. , 1976, The New England journal of medicine.
[78] B. Coiffier. Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma patients. , 1999, Haematologica.
[79] J. Laszlo,et al. Essential thrombocythemia: an interim report from the Polycythemia Vera Study Group. , 1986, Seminars in hematology.